XOMA Q2 net loss $5.4M; revenue $1.7M, cash $31.4M; two royalty deals in H1

XOMA Royalty Corp

2023-Q2 EPS reported -$1.57 revenue$2,095,000

Total revenue $1.7M (Q2 2022: $1.0M), driven by $1.1M milestone from Janssen license.
Net loss $5.4M vs $4.7M in Q2 2022; includes $1.6M non-cash impairment on Bioasis royalty.
Cash and equivalents $31.4M at June 30, 2023, down from $57.8M at Dec 31, 2022.
Net cash used in operations $7.2M, including $4.1M one-time arbitration settlement cost.
Expects lower milestone receipts in 2023 due to partner delays; cash sufficient for multiple years.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

XOMA Royalty Corp reported the quarter ended June 30, 2023 results: revenue total revenues of $1.7 million, net income Net loss for the second quarter of 2023 was $5.4 million.

Period: the quarter ended June 30, 2023
Revenue: total revenues of $1.7 million
Net income: Net loss for the second quarter of 2023 was $5.4 million
Result: reported results

Exact text from the filing

XOMA recorded total revenues of $1.7 million for the second quarter of 2023

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

XOMA Royalty Corp filing history →

Source: SEC EDGAR

accession 0001193125-23-205589

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.